TenAcea develops an AI platform to accelerate the development of innovative drugs for incurable diseases. AstraZeneca, Merck, Pfizer and Teva will invest in the company, support it and even provide it with clinical data.
"Artificial intelligence and machine learning can solve key problems in the fields of computational biology and chemistry," says AION Labs CEO Mati Gil. The company's platform is designed to accelerate a pioneering and promising approach in the world of drug discovery called "targeted protein degradation"